Moleculin Biotech

Moleculin Biotech Net Margin

The Net Profit Margin of Moleculin Biotech (MBRX) as of Nov 3, 2026 is -108,944.44 %.

Net Margin

-108,944.44 %

Last updated:

Net Profit Margin of Moleculin Biotech is 2017 -108,944.44 % . Net Profit Margin of Moleculin Biotech was 2016 - . It decreases by % lower compared to the previous year.

The Moleculin Biotech Net Margin history

The Moleculin Biotech Net Margin history
YEARNet MarginYoY
-108,944.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Moleculin Biotech Stock analysis

What does Moleculin Biotech do? Moleculin Biotech Inc is a clinical-stage pharmaceutical company focused on developing treatments for cancers. Its drug candidates include Annamycin for relapsed or refractory acute myeloid leukemia and lung metastases, WP1066 as a p-STAT3 inhibitor targeting brain tumors and pancreatic cancer, WP1220 for cutaneous T-cell lymphoma, and WP1732, WP1122, and WP1234 for AML, pancreatic cancer, and brain tumors through glycolysis inhibition. The company generates revenue through the development and potential commercialization of these clinical-stage drugs, targeting oncology specialists and healthcare providers in the pharmaceutical sector. Moleculin's products are positioned for late-stage clinical trials with potential partnerships for drug development and commercialization. The company's primary revenue stream comes from the progression of its drug candidates through clinical trials, with potential future sales once regulatory approvals are secured. Annamycin, WP1066, WP1220, WP1732, WP1122, and WP1234 are the key products under development, each targeting specific cancer types such as AML, brain tumors, pancreatic cancer, and cutaneous T-cell lymphoma. Healthcare providers and oncology specialists are the primary buyers of these future products, as they will prescribe them to patients in clinical settings. Moleculin Biotech's business model relies on advancing its pipeline of oncology-focused drug candidates through clinical trials, with the goal of securing partnerships or licensing agreements with larger pharmaceutical companies for further development and commercialization. The company's products are designed to address unmet medical needs in cancer treatment, targeting segments including hematological malignancies, solid tumors, and skin cancers. Revenue is anticipated once drugs receive regulatory approval and enter the market, with current focus on completing clinical trials to demonstrate efficacy and safety. Moleculin Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moleculin Biotech stock

Net Profit Margin of Moleculin Biotech is -108,944.44 % in 2017.

On Eulerpool you can find the complete historical development of Net Profit Margin Moleculin Biotech since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Moleculin Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Moleculin Biotech

All Key Metrics — Moleculin Biotech